MCID: MGK001
MIFTS: 63

Megakaryocytic Leukemia

Categories: Rare diseases, Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Megakaryocytic Leukemia

MalaCards integrated aliases for Megakaryocytic Leukemia:

Name: Megakaryocytic Leukemia 38 12 15
Acute Megakaryoblastic Leukemia 12 76 53 59 6
Acute Megakaryocytic Leukemias 12 73
Acute Megakaryocytic Leukemia 53 59
Acute Myeloid Leukemia M7 53 59
Aml M7 53 59
Amkl 53 59
Acute Megakaryoblastic Leukaemia, Fab M7 12
Acute Megakaryoblastic Leukemia, Fab M7 12
Acute Myeloblastic Leukemia Type 7 53
Leukemia, Megakaryoblastic, Acute 44
Megakaryoblastic Leukemia, Acute 13
Megakaryoblastic Leukemia Acute 55
Leukemia, Myelocytic, Acute 73
Megakaryocytic Myelosis 12
Thrombocytic Leukaemia 12

Characteristics:

Orphanet epidemiological data:

59
acute megakaryoblastic leukemia
Inheritance: Not applicable; Age of onset: Childhood;

Classifications:



External Ids:

Disease Ontology 12 DOID:8761
ICD10 33 C94.2 C94.20
ICD9CM 35 207.2
MeSH 44 D007947
NCIt 50 C3170
Orphanet 59 ORPHA518
ICD10 via Orphanet 34 C94.2
UMLS via Orphanet 74 C0023462
UMLS 73 C0023462

Summaries for Megakaryocytic Leukemia

NIH Rare Diseases : 53 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 518Disease definitionAcute megakaryoblastic leukemia (AMKL) is a form of acute myeloid leukemia (AML; see this term) that occurs predominantly in childhood and particularly in children with Down syndrome (DS-AMKL). Nonspecific symptoms may be irritability, weakness, and dizziness while specific symptoms include pallor, fever, mucocutaneous bleeding, hepatosplenomegaly, neurological manifestations and rarely lymphadenopathy. Acute panmyelosis with myelofibrosis (see this term)may also be associated with AMKL. In contrast to DS-AMKL (around 80 % survival), non-DS-AMKL is an AML subgroup associated with poor prognosis.Visit the Orphanet disease page for more resources.

MalaCards based summary : Megakaryocytic Leukemia, also known as acute megakaryoblastic leukemia, is related to leukemia and acute leukemia, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Megakaryocytic Leukemia is GATA1 (GATA Binding Protein 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Cyclophosphamide and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Increased cell death HMECs cells and Reduced mammosphere formation

Disease Ontology : 12 A leukemia that derives from blood-forming tissue in which megakaryocytes proliferate in the bone marrow and circulate in the blood in large numbers.

Wikipedia : 76 Acute megakaryoblastic leukemia (AMKL) is a form of leukemia where a majority of the blasts are... more...

Related Diseases for Megakaryocytic Leukemia

Diseases related to Megakaryocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Related Disease Score Top Affiliating Genes
1 leukemia 30.3 CSF2 JAK2 MKL1 RUNX1 TP53
2 acute leukemia 29.7 IL3 JAK2 MPO RUNX1
3 myelofibrosis 29.2 GATA1 IL3 JAK2 THPO
4 myeloid leukemia 28.9 CSF2 IL3 JAK2 RUNX1 TP53
5 essential thrombocythemia 25.8 GATA1 IL11 IL3 ITGA2B JAK2 MPO
6 leukemia, acute myeloid 25.7 CSF2 GATA1 IL3 JAK2 KITLG MPO
7 acute megakaryoblastic leukemia in down syndrome 12.3
8 acute megakaryoblastic leukemia without down syndrome 12.2
9 megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13) 10.8 MKL1 RBM15
10 seborrheic infantile dermatitis 10.7 CSF2 IL3
11 anemia of prematurity 10.5 CSF2 IL3 KITLG
12 refractory anemia 10.4 IL3 JAK2 RUNX1
13 leukocyte disease 10.4 CSF2 IL3 KITLG
14 trichosporonosis 10.4 CBS CSF2
15 acute basophilic leukemia 10.3 GATA1 MPO
16 retinitis pigmentosa and erythrocytic microcytosis 10.3 IL3 JAK2
17 down syndrome 10.2
18 germ cells tumors 10.2
19 neutrophilia, hereditary 10.1 CSF2 JAK2
20 acute lymphocytic leukemia 10.0 CSF2 RUNX1 TP53
21 acquired thrombocytopenia 9.9 IL11 THPO
22 female reproductive endometrioid cancer 9.9 PTEN TP53
23 amegakaryocytic thrombocytopenia, congenital 9.9 IL3 THPO
24 pulmonary hypertension 9.9
25 hematopoietic stem cell transplantation 9.9
26 hepatitis 9.9
27 sarcoma 9.9
28 myeloid sarcoma 9.9
29 hypoxia 9.9
30 severe congenital neutropenia 9.8 CSF2 IL3 JAK2 KITLG RUNX1
31 multiple cranial nerve palsy 9.8 MPO RUNX1 TP53
32 pancytopenia 9.8 CSF2 IL3 THPO
33 thrombocytopenic purpura, autoimmune 9.7 IL11 ITGA2B THPO
34 beckwith-wiedemann syndrome 9.7
35 teratoma 9.7
36 cerebritis 9.7
37 pneumonia 9.7
38 malignant teratoma 9.7
39 mediastinitis 9.7
40 vasculitis 9.7
41 diabetes insipidus 9.7
42 periostitis 9.7
43 1q duplications 9.7
44 trisomy 1q 9.7
45 acquired central diabetes insipidus 9.7
46 exanthema subitum 9.7 ITGA2B KITLG THPO
47 testicular germ cell tumor 9.7 KITLG PTEN TP53
48 erythrocytosis, familial, 1 9.7 IL3 JAK2 THPO
49 thrombocytopenia-absent radius syndrome 9.7 GATA1 JAK2 THPO
50 juvenile myelomonocytic leukemia 9.6 CSF2 JAK2 JAK3 RUNX1

Comorbidity relations with Megakaryocytic Leukemia via Phenotypic Disease Network (PDN):


Acquired Thrombocytopenia Deficiency Anemia
Neutropenia

Graphical network of the top 20 diseases related to Megakaryocytic Leukemia:



Diseases related to Megakaryocytic Leukemia

Symptoms & Phenotypes for Megakaryocytic Leukemia

UMLS symptoms related to Megakaryocytic Leukemia:


angina pectoris, chest pain, edema

GenomeRNAi Phenotypes related to Megakaryocytic Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death HMECs cells GR00103-A-0 9.43 CSF2 IL11 IL3 JAK2 PTEN TP53
2 Reduced mammosphere formation GR00396-S 9.23 CBS GATA1 IL6R ITGA2B JAK3 PTEN
3 Decreased viability in HMC1.1 cells GR00105-A-0 9.16 JAK3 LYN

MGI Mouse Phenotypes related to Megakaryocytic Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.31 KITLG IL6R ITGA2B LYN CSF2 JAK2
2 cellular MP:0005384 10.26 KITLG IL6R ITGA2B CSF2 JAK2 GATA1
3 homeostasis/metabolism MP:0005376 10.24 KITLG IL6R ITGA2B CSF2 JAK2 GATA1
4 immune system MP:0005387 10.2 KITLG IL6R ITGA2B CSF2 JAK2 GATA1
5 endocrine/exocrine gland MP:0005379 10.09 IL6R KITLG CSF2 JAK2 JAK3 TP53
6 embryo MP:0005380 10.06 GATA1 KITLG ITGA2B CSF2 JAK2 TP53
7 integument MP:0010771 9.91 KITLG CSF2 JAK2 GATA1 TP53 PTEN
8 liver/biliary system MP:0005370 9.81 KITLG IL6R JAK2 GATA1 TP53 PTEN
9 mortality/aging MP:0010768 9.8 KITLG IL6R CSF2 JAK2 GATA1 JAK3
10 neoplasm MP:0002006 9.23 KITLG IL6R CSF2 JAK2 TP53 PTEN

Drugs & Therapeutics for Megakaryocytic Leukemia

Drugs for Megakaryocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 218)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
2
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
3
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 1 52-24-4 5453
4 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
8 Antilymphocyte Serum Phase 4,Phase 2,Phase 1
9
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
10
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
11
Daunorubicin Approved Phase 3,Phase 2,Phase 1 20830-81-3 30323
12
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
13
Idarubicin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58957-92-9 42890
14
Mesna Approved, Investigational Phase 3 3375-50-6 598
15
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
16
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
17
Thioguanine Approved Phase 3,Phase 1 154-42-7 2723601
18
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4
19
Clofarabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 123318-82-1 119182
20
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
21
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
22
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
23
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
24
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1 216503-57-0
25
Arsenic trioxide Approved, Investigational Phase 2, Phase 3,Phase 1 1327-53-3 518740
26
Azacitidine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 320-67-2 9444
27
Melphalan Approved Phase 2, Phase 3,Phase 3,Phase 1 148-82-3 4053 460612
28
Carmustine Approved, Investigational Phase 3 154-93-8 2578
29
Hydroxyurea Approved Phase 3 127-07-1 3657
30
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
31
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
32
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
33
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
34
Cyproheptadine Approved Phase 3 129-03-3 2913
35
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
36
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538 444795
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
38
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
39
Butyric Acid Experimental, Investigational Phase 3 107-92-6 264
40
tipifarnib Investigational Phase 3,Phase 2,Phase 1 192185-72-1 159324
41 Staurosporine Experimental Phase 3,Phase 1 62996-74-1
42 Vaccines Phase 3
43 Gemtuzumab Phase 2, Phase 3,Phase 3,Phase 1
44 Analgesics Phase 3,Phase 2,Phase 1
45 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 188)
# Name Status NCT ID Phase Drugs
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission Unknown status NCT00454168 Phase 3
3 Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
4 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
5 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
6 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
7 Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00004128 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide
8 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
9 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
10 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
11 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
12 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
13 Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Completed NCT00093470 Phase 3 Tipifarnib
14 Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00003190 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar
15 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
16 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
17 Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00052299 Phase 3 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
18 Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
19 Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
20 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
21 Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia Completed NCT00112554 Phase 3 cytarabine;laromustine
22 S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
23 Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00002719 Phase 3 amsacrine;carmustine;cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
24 flt3L in Treating Patients With Acute Myeloid Leukemia Completed NCT00006223 Phase 3
25 High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00002945 Phase 3 cyclophosphamide;cytarabine;etoposide;idarubicin;melphalan
26 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
27 Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy Active, not recruiting NCT01307579 Phase 3 caspofungin acetate;fluconazole
28 Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT02085408 Phase 3 clofarabine;daunorubicin hydrochloride;cytarabine;decitabine
29 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
30 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
31 Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
32 Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00003405 Phase 2 amifostine trihydrate;bromodeoxyuridine;cytarabine;idarubicin;idoxuridine;isotretinoin;mitoxantrone hydrochloride
33 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant Unknown status NCT02038153 Phase 1, Phase 2 Lenalidomide
34 Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia Unknown status NCT00838240 Phase 1, Phase 2 clofarabine;cytarabine;idarubicin
35 Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Unknown status NCT00425477 Phase 2 bexarotene
36 VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
37 Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00006084 Phase 2
38 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
39 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
40 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
41 Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Completed NCT00666588 Phase 2 idarubicin;cytarabine;bortezomib;etoposide
42 Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission Completed NCT01020734 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;methotrexate
43 Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Completed NCT00372619 Phase 1, Phase 2 clofarabine;cytarabine;methotrexate
44 Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003396 Phase 2 cyclophosphamide;melphalan
45 Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome Completed NCT00002547 Phase 2 busulfan;cyclophosphamide;cyclosporine;cytarabine;methotrexate
46 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
47 Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer Completed NCT00003335 Phase 2 busulfan;cyclosporine;melphalan;methylprednisolone
48 Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia Completed NCT01870596 Phase 2 Cytarabine;CHK1 Inhibitor SCH 900776
49 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Completed NCT01361464 Phase 2 Tipifarnib
50 Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia Completed NCT02144675 Phase 2 choline magnesium trisalicylate;idarubicin;cytarabine

Search NIH Clinical Center for Megakaryocytic Leukemia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Megakaryocytic Leukemia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: leukemia, megakaryoblastic, acute

Genetic Tests for Megakaryocytic Leukemia

Anatomical Context for Megakaryocytic Leukemia

MalaCards organs/tissues related to Megakaryocytic Leukemia:

41
Myeloid, Bone, Bone Marrow, Monocytes, Liver, B Cells, Lymph Node

Publications for Megakaryocytic Leukemia

Articles related to Megakaryocytic Leukemia:

(show top 50) (show all 197)
# Title Authors Year
1
Down-syndrome-like acute megakaryoblastic leukemia in a patient with Cornelia de Lange syndrome. ( 29217785 )
2017
2
Prognostic Impact of Specific Molecular Profiles in Pediatric Acute Megakaryoblastic Leukemia in Non-Down Syndrome. ( 28063190 )
2017
3
ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia. ( 28292442 )
2017
4
A pediatric case of acute megakaryocytic leukemia with double chimeric transcripts of CBFA2T3-GLIS2 and DHH-RHEBL1. ( 29043865 )
2017
5
Clinical Courses of Two Pediatric Patients with Acute Megakaryoblastic Leukemia Harboring the CBFA2T3-GLIS2 Fusion Gene. ( 27094503 )
2016
6
CCND1-BCL2 Gene Network: A direct target of Amifostine in human acute megakaryocytic leukemia cells. ( 27762064 )
2016
7
Acute megakaryoblastic leukemia, unlike acute erythroid leukemia, predicts an unfavorable outcome after allogeneic HSCT. ( 27244257 )
2016
8
Post-allogeneic stem cell transplant extramedullary relapse of acute megakaryoblastic leukemia initially detected by elevated WT1 mRNA levels in peripheral blood. ( 27941279 )
2016
9
Acute Megakaryoblastic Leukemia with Myelodysplasia-related Changes Associated with ATM Gene Deletion. ( 27301517 )
2016
10
Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial. ( 25913479 )
2015
11
MiR-125b and miR-99a encoded on chromosome 21 co-regulate vincristine resistance in childhood acute megakaryoblastic leukemia. ( 25571789 )
2015
12
Megakaryocytic leukemia 1 directs a histone h3 lysine 4 methyltransferase complex to regulate hypoxic pulmonary hypertension. ( 25646298 )
2015
13
MN1-Fli1 oncofusion transforms murine hematopoietic progenitor cells into acute megakaryoblastic leukemia cells. ( 26690545 )
2015
14
Acute megakaryocytic leukemia: What have we learned. ( 26228843 )
2015
15
Presentation of Acute Megakaryoblastic Leukemia Associated with a GATA-1 Mutation Mimicking the Eruption of Transient Myeloproliferative Disorder. ( 26205501 )
2015
16
Acute megakaryocytic leukemia is associated with worse outcomes than other types of acute myeloid leukemia. ( 25498456 )
2014
17
Relapse of acute megakaryocytic leukemia as hepatic myeloid sarcoma after allogeneic haploidentical hematopoietic stem cell transplantation. ( 24916785 )
2014
18
Extramedullary Tumor of Cerebral Falx: An Unusual Presentation of Acute Megakaryocytic Leukemia. ( 24663070 )
2014
19
Megakaryocytic leukemia 1 (MKL1) regulates hypoxia induced pulmonary hypertension in rats. ( 24647044 )
2014
20
Pan myeloid antigen-negative pediatric acute megakaryoblastic leukemia. ( 24962432 )
2014
21
LincRNAs MONC and MIR100HG act as oncogenes in acute megakaryoblastic leukemia. ( 25027842 )
2014
22
Hemophagocytosis in acute megakaryocytic leukemia: hemophagocytosis or emperipolesis? ( 23823115 )
2013
23
Megakaryocytic leukemia 1 (MKL1) ties the epigenetic machinery to hypoxia-induced transactivation of endothelin-1. ( 23625963 )
2013
24
NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. ( 23531517 )
2013
25
Transposon mutagenesis reveals cooperation of ETS family transcription factors with signaling pathways in erythro-megakaryocytic leukemia. ( 23533276 )
2013
26
Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia. ( 23874683 )
2013
27
Blast cell deficiency of CD11a as a marker of acute megakaryoblastic leukemia and transient myeloproliferative disease in children with and without Down syndrome. ( 23450818 )
2013
28
Mutation characterization in the GATA-1 gene in patients with Down's Syndrome diagnosed with transient abnormal myelopoiesis or acute megakaryoblastic leukemia. ( 24196768 )
2013
29
Case study interpretation-New Orleans: case 1. Extramedullary acute megakaryocytic leukemia. ( 23283835 )
2013
30
Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes. ( 23980066 )
2013
31
Differential diagnosis of myelofibrosis based on WHO 2008 criteria: acute panmyelosis with myelofibrosis, acute megakaryoblastic leukemia with myelofibrosis, primary myelofibrosis and myelodysplastic syndrome with myelofibrosis. ( 23693053 )
2013
32
Acute megakaryoblastic leukemia in a patient with xeroderma pigmentosum: discussion of pathophysiological, prognostic, and toxicological aspects. ( 23207728 )
2013
33
Hematopoietic overexpression of the transcription factor Erg induces lymphoid and erythro-megakaryocytic leukemia. ( 22936051 )
2012
34
Acute megakaryoblastic leukemia with increased hematogones in children. ( 22983420 )
2012
35
An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. ( 23153540 )
2012
36
Identification of TRIB1 R107L gain-of-function mutation in human acute megakaryocytic leukemia. ( 22294728 )
2012
37
Development of acute megakaryoblastic leukemia with isochromosome (12p) after a primary mediastinal germ cell tumor in Korea. ( 21860563 )
2011
38
Identification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia. ( 21640380 )
2011
39
A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapy. ( 22110660 )
2011
40
Acute megakaryoblastic leukemia with a four-way variant translocation originating the RBM15-MKL1 fusion gene. ( 21370421 )
2011
41
Alpha- and beta-synucleins are new diagnostic tools for acute erythroid leukemia and acute megakaryoblastic leukemia. ( 21264917 )
2011
42
Acute megakaryoblastic leukemia without GATA1 mutation after transient myeloproliferative disorder in an infant without Down syndrome. ( 21205752 )
2011
43
Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects. ( 21599579 )
2011
44
Congenital acute megakaryocytic leukemia. ( 22557786 )
2011
45
Acute megakaryocytic leukemia (AMKL,FAB;M7) with Beckwith-Wiedemann syndrome. ( 20589645 )
2010
46
A rare case of GATA1 negative chemoresistant acute megakaryocytic leukemia in an 8-month-old infant with trisomy 21. ( 20108342 )
2010
47
Ring/marker chromosome derived from chromosome 7 in childhood acute megakaryoblastic leukemia with monosomy 7. ( 20809201 )
2010
48
Hypercalcemia in pediatric acute megakaryocytic leukemia: case report and review of the literature. ( 19415024 )
2009
49
The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. ( 19287095 )
2009
50
Bone fracture: an unusual presentation of acute megakaryoblastic leukemia. ( 19206010 )
2009

Variations for Megakaryocytic Leukemia

ClinVar genetic disease variations for Megakaryocytic Leukemia:

6
(show all 30)
# Gene Variation Type Significance SNP ID Assembly Location
1 GATA1 NM_002049.3(GATA1): c.154_173dup20 (p.Ala59Glnfs) duplication Pathogenic rs398124628 GRCh37 Chromosome X, 48649670: 48649689
2 GATA1 NM_002049.3(GATA1): c.154_173dup20 (p.Ala59Glnfs) duplication Pathogenic rs398124628 GRCh38 Chromosome X, 48791263: 48791282
3 PTEN NM_000314.6(PTEN): c.406T> C (p.Cys136Arg) single nucleotide variant Pathogenic rs786201044 GRCh37 Chromosome 10, 89692922: 89692922
4 PTEN NM_000314.6(PTEN): c.406T> C (p.Cys136Arg) single nucleotide variant Pathogenic rs786201044 GRCh38 Chromosome 10, 87933165: 87933165
5 SLC9A2 NM_003048.5(SLC9A2): c.2168delC (p.Gln725Serfs) deletion Uncertain significance rs864309496 GRCh37 Chromosome 2, 103324677: 103324677
6 SLC9A2 NM_003048.5(SLC9A2): c.2168delC (p.Gln725Serfs) deletion Uncertain significance rs864309496 GRCh38 Chromosome 2, 102708218: 102708218
7 ACPP NM_001134194.1(ACPP): c.848_850delTCA (p.Ile284del) deletion Uncertain significance rs864309497 GRCh38 Chromosome 3, 132349986: 132349988
8 ACPP NM_001134194.1(ACPP): c.848_850delTCA (p.Ile284del) deletion Uncertain significance rs864309497 GRCh37 Chromosome 3, 132068830: 132068832
9 MDGA1 NM_153487.3(MDGA1): c.2674T> G (p.Phe892Val) single nucleotide variant Uncertain significance rs864309493 GRCh38 Chromosome 6, 37638307: 37638307
10 MDGA1 NM_153487.3(MDGA1): c.2674T> G (p.Phe892Val) single nucleotide variant Uncertain significance rs864309493 GRCh37 Chromosome 6, 37606083: 37606083
11 PCF11 NM_015885.3(PCF11): c.3223delT (p.Phe1075Leufs) deletion Uncertain significance rs864309498 GRCh37 Chromosome 11, 82880600: 82880600
12 PCF11 NM_015885.3(PCF11): c.3223delT (p.Phe1075Leufs) deletion Uncertain significance rs864309498 GRCh38 Chromosome 11, 83169558: 83169558
13 CORO7 NM_024535.4(CORO7): c.2772+50C> T single nucleotide variant Uncertain significance rs864309494 GRCh38 Chromosome 16, 4355236: 4355236
14 CORO7 NM_024535.4(CORO7): c.2772+50C> T single nucleotide variant Uncertain significance rs864309494 GRCh37 Chromosome 16, 4405237: 4405237
15 TP53 NM_000546.5(TP53): c.636delT (p.Arg213Aspfs) deletion Pathogenic rs864309495 GRCh38 Chromosome 17, 7674895: 7674895
16 TP53 NM_000546.5(TP53): c.636delT (p.Arg213Aspfs) deletion Pathogenic rs864309495 GRCh37 Chromosome 17, 7578213: 7578213
17 RASAL3 NM_022904.2(RASAL3): c.-5C> G single nucleotide variant Uncertain significance rs76267899 GRCh38 Chromosome 19, 15464363: 15464363
18 RASAL3 NM_022904.2(RASAL3): c.-5C> G single nucleotide variant Uncertain significance rs76267899 GRCh37 Chromosome 19, 15575174: 15575174
19 MT-ND6 NC_012920.1: m.14372C> A single nucleotide variant Uncertain significance rs386829210 GRCh37 Chromosome MT, 14372: 14372
20 MT-ND6 NC_012920.1: m.14372C> A single nucleotide variant Uncertain significance rs386829210 GRCh38 Chromosome MT, 14372: 14372
21 JAK3 NM_000215.3(JAK3): c.1715C> T (p.Ala572Val) single nucleotide variant Likely pathogenic rs121913504 GRCh37 Chromosome 19, 17948009: 17948009
22 JAK3 NM_000215.3(JAK3): c.1715C> T (p.Ala572Val) single nucleotide variant Likely pathogenic rs121913504 GRCh38 Chromosome 19, 17837200: 17837200
23 JAK3 NM_000215.3(JAK3): c.1503G> C (p.Gln501His) single nucleotide variant Likely pathogenic rs201283129 GRCh38 Chromosome 19, 17838329: 17838329
24 JAK3 NM_000215.3(JAK3): c.1970G> A (p.Arg657Gln) single nucleotide variant Likely pathogenic rs758959409 GRCh37 Chromosome 19, 17945969: 17945969
25 JAK3 NM_000215.3(JAK3): c.1970G> A (p.Arg657Gln) single nucleotide variant Likely pathogenic rs758959409 GRCh38 Chromosome 19, 17835160: 17835160
26 JAK3 NM_000215.3(JAK3): c.1503G> T (p.Gln501His) single nucleotide variant Likely pathogenic rs201283129 GRCh37 Chromosome 19, 17949138: 17949138
27 JAK3 NM_000215.3(JAK3): c.1503G> T (p.Gln501His) single nucleotide variant Likely pathogenic rs201283129 GRCh38 Chromosome 19, 17838329: 17838329
28 JAK3 NM_000215.3(JAK3): c.1503G> C (p.Gln501His) single nucleotide variant Likely pathogenic rs201283129 GRCh37 Chromosome 19, 17949138: 17949138
29 JAK3 NM_000215.3(JAK3): c.260T> C (p.Ile87Thr) single nucleotide variant Likely pathogenic rs1057519770 GRCh37 Chromosome 19, 17954634: 17954634
30 JAK3 NM_000215.3(JAK3): c.260T> C (p.Ile87Thr) single nucleotide variant Likely pathogenic rs1057519770 GRCh38 Chromosome 19, 17843825: 17843825

Copy number variations for Megakaryocytic Leukemia from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 158678 21 35304204 35704075 Loss RUNX1 Acute megakaryoblastic leukaemia

Expression for Megakaryocytic Leukemia

Search GEO for disease gene expression data for Megakaryocytic Leukemia.

Pathways for Megakaryocytic Leukemia

Pathways related to Megakaryocytic Leukemia according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 CSF2 IL11 IL3 IL6R ITGA2B JAK2
2
Show member pathways
13.82 CSF2 IL11 IL3 IL6R ITGA2B JAK2
3
Show member pathways
13.64 CSF2 IL11 IL3 IL6R JAK2 JAK3
4
Show member pathways
13.48 IL11 IL3 IL6R ITGA2B JAK2 JAK3
5
Show member pathways
13.29 CSF2 IL11 IL3 IL6R ITGA2B JAK2
6
Show member pathways
13.25 CSF2 IL11 IL3 IL6R ITGA2B JAK2
7
Show member pathways
13.24 CSF2 IL11 IL3 IL6R JAK2 KITLG
8
Show member pathways
13.23 CSF2 GATA1 IL3 ITGA2B JAK2 JAK3
9
Show member pathways
13.05 IL3 ITGA2B KITLG LYN PTEN THPO
10
Show member pathways
12.92 IL3 IL6R ITGA2B JAK2 JAK3 KITLG
11
Show member pathways
12.85 CSF2 IL3 MPO PTEN RUNX1 TP53
12
Show member pathways
12.81 IL11 ITGA2B JAK2 JAK3 PTEN
13 12.74 IL3 IL6R ITGA2B JAK2 JAK3 KITLG
14
Show member pathways
12.73 IL6R JAK2 JAK3 PTEN TP53
15
Show member pathways
12.57 CSF2 IL11 IL3 IL6R JAK2 JAK3
16
Show member pathways
12.55 CSF2 JAK2 LYN PTEN TP53
17
Show member pathways
12.39 IL6R JAK2 JAK3 RUNX1
18 12.23 CSF2 IL3 MPO RUNX1 TP53
19
Show member pathways
12.22 IL11 IL6R JAK2 JAK3
20
Show member pathways
12.16 IL3 JAK2 KITLG LYN PTEN
21
Show member pathways
12.13 CSF2 IL3 JAK2 JAK3 LYN
22 12.12 GATA1 IL3 JAK2 JAK3 KITLG LYN
23 12.11 IL6R ITGA2B PTEN TP53
24
Show member pathways
12.07 IL11 IL3 IL6R JAK2 KITLG THPO
25 12.01 GATA1 IL11 IL3 KITLG RUNX1 THPO
26 11.98 IL6R JAK2 JAK3 TP53
27 11.93 IL3 IL6R PTEN TP53
28 11.88 IL3 IL6R JAK2 JAK3 LYN
29
Show member pathways
11.87 CSF2 IL6R JAK2 JAK3
30 11.87 CSF2 IL11 IL3 ITGA2B KITLG MPO
31 11.81 ITGA2B PTEN TP53
32 11.73 GATA1 KITLG MPO
33 11.52 ITGA2B JAK2 LYN
34 11.49 IL11 IL3 IL6R KITLG
35 11.31 CSF2 GATA1 IL3 ITGA2B KITLG RUNX1
36 11.27 CSF2 IL11 IL3
37 11.15 CSF2 IL11 IL3 IL6R ITGA2B KITLG
38 10.88 KITLG LYN

GO Terms for Megakaryocytic Leukemia

Cellular components related to Megakaryocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 CSF2 IL11 IL3 IL6R KITLG MPO
2 extrinsic component of cytoplasmic side of plasma membrane GO:0031234 8.8 JAK2 JAK3 LYN

Biological processes related to Megakaryocytic Leukemia according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.97 CSF2 IL11 IL3 KITLG PF4 THPO
2 MAPK cascade GO:0000165 9.93 CSF2 IL3 JAK2 JAK3 KITLG
3 regulation of cell proliferation GO:0042127 9.92 CSF2 JAK2 JAK3 LYN PF4
4 response to lipopolysaccharide GO:0032496 9.91 JAK2 MPO PF4 TRIB1
5 positive regulation of cell proliferation GO:0008284 9.86 CSF2 IL11 IL3 IL6R JAK2 KITLG
6 peptidyl-tyrosine phosphorylation GO:0018108 9.8 CSF2 IL3 JAK2 JAK3 LYN
7 peptidyl-tyrosine autophosphorylation GO:0038083 9.77 JAK2 JAK3 LYN
8 positive regulation of DNA replication GO:0045740 9.75 CSF2 IL3 KITLG
9 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.73 CSF2 GATA1 PF4
10 regulation of megakaryocyte differentiation GO:0045652 9.73 GATA1 ITGA2B PF4 RUNX1
11 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.66 CSF2 PF4
12 interleukin-6-mediated signaling pathway GO:0070102 9.65 IL6R JAK2
13 positive regulation of leukocyte migration GO:0002687 9.65 ITGA2B KITLG
14 positive regulation of macrophage differentiation GO:0045651 9.65 PF4 TRIB1
15 embryonic hemopoiesis GO:0035162 9.65 GATA1 IL3 KITLG
16 regulation of myeloid cell differentiation GO:0045637 9.64 CSF2 RUNX1
17 enzyme linked receptor protein signaling pathway GO:0007167 9.64 JAK2 JAK3
18 regulation of B cell receptor signaling pathway GO:0050855 9.63 LYN RUNX1
19 regulation of JAK-STAT cascade GO:0046425 9.63 JAK2 JAK3
20 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.63 JAK2 JAK3 LYN
21 tyrosine phosphorylation of STAT protein GO:0007260 9.62 JAK2 JAK3
22 erythrocyte differentiation GO:0030218 9.62 GATA1 JAK2 JAK3 LYN
23 regulation of cytokine-mediated signaling pathway GO:0001959 9.61 IL3 RUNX1
24 megakaryocyte differentiation GO:0030219 9.6 GATA1 IL11
25 positive regulation of hematopoietic stem cell proliferation GO:1902035 9.58 KITLG THPO
26 negative regulation of cytolysis GO:0045918 9.57 CSF2 PF4
27 cytokine-mediated signaling pathway GO:0019221 9.56 CSF2 IL11 IL3 IL6R JAK2 JAK3
28 regulation of B cell apoptotic process GO:0002902 9.55 LYN PTEN
29 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.55 CSF2 IL3 IL6R JAK2 LYN
30 dendritic cell differentiation GO:0097028 9.54 CSF2 GATA1 LYN
31 positive regulation of mast cell proliferation GO:0070668 9.51 KITLG LYN
32 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.23 GATA1 IL11 IL3 IL6R JAK2 KITLG
33 negative regulation of apoptotic process GO:0043066 10.06 GATA1 KITLG MPO PTEN TP53
34 negative regulation of cell proliferation GO:0008285 10.02 GATA1 JAK2 LYN PTEN TP53

Molecular functions related to Megakaryocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.72 CBS IL6R LYN PTEN TP53
2 protein tyrosine kinase activity GO:0004713 9.65 CSF2 IL3 JAK2 JAK3 LYN
3 growth factor activity GO:0008083 9.55 CSF2 IL11 IL3 KITLG THPO
4 non-membrane spanning protein tyrosine kinase activity GO:0004715 9.54 JAK2 JAK3 LYN
5 platelet-derived growth factor receptor binding GO:0005161 9.4 LYN PTEN
6 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.35 CSF2 IL3 JAK2 JAK3 KITLG
7 cytokine activity GO:0005125 9.1 CSF2 IL11 IL3 KITLG PF4 THPO
8 protein binding GO:0005515 10.36 CBS CSF2 GATA1 IL11 IL6R ITGA2B

Sources for Megakaryocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....